Trials / Completed
CompletedNCT00245362
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Cell Genesys · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and effectiveness of CG8020 and CG2505.
Detailed description
To evaluate clinical and laboratory safety of CG 8020 and CG 2505 and to evaluate the efficacy of CG 8020 and CG 2505 as measured by clinical benefit response, progression-free survival, survival and CA 19-9 serum marker levels in chemotherapy naive or experienced patients with nonresectable or metastatic adenocarcinoma of the pancreas
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CG 8020 and CG 2505 |
Timeline
- Start date
- 2002-06-01
- Completion
- 2004-06-01
- First posted
- 2005-10-28
- Last updated
- 2005-10-28
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00245362. Inclusion in this directory is not an endorsement.